image
Healthcare - Biotechnology - NASDAQ - US
$ 3.58
0.562 %
$ 178 M
Market Cap
4.59
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PBYI stock under the worst case scenario is HIDDEN Compared to the current market price of 3.58 USD, Puma Biotechnology, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PBYI stock under the base case scenario is HIDDEN Compared to the current market price of 3.58 USD, Puma Biotechnology, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PBYI stock under the best case scenario is HIDDEN Compared to the current market price of 3.58 USD, Puma Biotechnology, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PBYI

image
$3.8$3.8$3.7$3.7$3.6$3.6$3.5$3.5$3.4$3.4$3.3$3.3$3.2$3.2$3.1$3.1$3.0$3.0$2.9$2.9$2.8$2.8$2.7$2.715 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
230 M REVENUE
-2.19%
31 M OPERATING INCOME
-5.13%
30.3 M NET INCOME
40.23%
38.9 M OPERATING CASH FLOW
44.09%
-20.4 M INVESTING CASH FLOW
-6.87%
-33.8 M FINANCING CASH FLOW
0.00%
46 M REVENUE
-22.12%
3.98 M OPERATING INCOME
-70.19%
2.97 M NET INCOME
-84.59%
3.61 M OPERATING CASH FLOW
-76.86%
1.53 M INVESTING CASH FLOW
165.99%
-11.3 M FINANCING CASH FLOW
-0.01%
Balance Sheet Puma Biotechnology, Inc.
image
Current Assets 148 M
Cash & Short-Term Investments 101 M
Receivables 32 M
Other Current Assets 14.7 M
Non-Current Assets 65.7 M
Long-Term Investments 0
PP&E 5.09 M
Other Non-Current Assets 60.6 M
47.33 %15.01 %6.88 %28.40 %Total Assets$213.3m
Current Liabilities 96.1 M
Accounts Payable 5.51 M
Short-Term Debt 50.9 M
Other Current Liabilities 39.7 M
Non-Current Liabilities 25.1 M
Long-Term Debt 23.2 M
Other Non-Current Liabilities 1.88 M
4.55 %41.97 %32.78 %19.15 %Total Liabilities$121.2m
EFFICIENCY
Earnings Waterfall Puma Biotechnology, Inc.
image
Revenue 230 M
Cost Of Revenue 64.4 M
Gross Profit 166 M
Operating Expenses 135 M
Operating Income 31 M
Other Expenses 688 K
Net Income 30.3 M
250m250m200m200m150m150m100m100m50m50m00230m(64m)166m(135m)31m(688k)30mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
72.06% GROSS MARGIN
72.06%
13.44% OPERATING MARGIN
13.44%
13.14% NET MARGIN
13.14%
32.87% ROE
32.87%
14.19% ROA
14.19%
23.14% ROIC
23.14%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Puma Biotechnology, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 30.3 M
Depreciation & Amortization 11.5 M
Capital Expenditures -56 K
Stock-Based Compensation 8.24 M
Change in Working Capital -3.54 M
Others -17.4 M
Free Cash Flow 38.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Puma Biotechnology, Inc.
image
PBYI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Puma Biotechnology, Inc.
image
Sold
0-3 MONTHS
312 K USD 6
3-6 MONTHS
0 USD 0
6-9 MONTHS
196 K USD 4
9-12 MONTHS
201 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq Listing Rule 5635(c)(4). businesswire.com - 2 weeks ago
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 3 weeks ago
Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, especially in pancreatic cancer, but pivotal data won't arrive until 2026. Alisertib's phase 2 trials in breast and lung cancer are ongoing, but lack of recent data keeps its potential speculative for now. seekingalpha.com - 3 weeks ago
Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com - 3 weeks ago
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award. businesswire.com - 1 month ago
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com - 1 month ago
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com - 2 months ago
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2 months ago
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss of 5 cents per share. zacks.com - 2 months ago
Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & Chief Executive Officer Jeff Ludwig - Chief Commercial Officer Heather Blaber - VP of Marketing Roger Storms - VP of Sales Maximo Nougues - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Operator Good afternoon. My name is Sherry, and I will be your conference call operator today. seekingalpha.com - 2 months ago
8. Profile Summary

Puma Biotechnology, Inc. PBYI

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 178 M
Dividend Yield 0.00%
Description Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Contact 10880 Wilshire Boulevard, Los Angeles, CA, 90024 https://www.pumabiotechnology.com
IPO Date April 24, 2012
Employees 172
Officers Mr. Mariann Ohanesian Senior Director of Investor Relations Mr. Douglas Hunt B.Sc., FRAPS Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer Mr. Alan H. Auerbach Founder, Chairman, President, Chief Executive Officer & Secretary Mr. Maximo F. Nougues Chief Financial Officer & Principal Accounting Officer